March 31, 2017

Company name:SanBio Co., Ltd.
Representative: Keita Mori, Representative Director and President
(TSE Mothers Code: 4592)
Contact: Yoshihiro Kakutani, Corporate Officer of Management Administration
(TEL. +81-3-6264-3481)

(Delayed) Notice Concerning Borrowing of Funds

SanBio Co., Ltd. (hereafter "the Company") announces that on March 31, 2017, it made a decision concerning the borrowing of funds as shown below.

1. Reasons for the borrowings

Currently, the Company is conducting a Phase 2b clinical trial of the regenerative cell medicine SB623 for the treatment of chronic stroke in North America together with its joint development partner Sumitomo Dainippon Pharma Co., Ltd. In addition, the Company is independently conducting a Phase 2 global clinical trial for the treatment of chronic traumatic brain injury across the US and Japan.

The Company plans to increase cash on hand with the borrowing to ensure the smooth progress of the above mentioned development.

2. Details of the borrowing

(1) Lender	Mitsubishi UFJ Trust and Banking Corporation
(2) Loan amount	¥900 million
(3) Interest rate	1.30%
(4) Drawdown date	March 31, 2017
(5) Loan period	Five (5) years
(6) Repayment method	Repayment in installments, starting after four (4) years

3. Outlook

The effect of this borrowing on the Company's consolidated financial results for the fiscal year ending January 31, 2018 is not significant.